‘High long-term efficacy’ with sonelokimab for hidradenitis suppurativa: Topline data

Adults who received sonelokimab for moderate to severe hidradenitis suppurativa experienced consistent disease improvement through 1 year, according to topline data.More than 67% of the participants who received sonelokimab (MoonLake Immunotherapeutics) in the phase 3 VELA-1 and VELA-2 clinical trials achieved Hidradenitis Suppurativa Clinical Response (HiSCR)75 by week 52 — an increase